|
Efficacy of the addition of cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies. |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Merck Sharp & Dohme; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Merck Sharp & Dohme; Novartis; Roche |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Merck Sharp & Dohme; Novartis |
|
|
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Italfarmaco; Lilly; Pfizer; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
|
|
Honoraria - Amgen; Bayer; Bayer; Bayer; Daiichi Sankyo; Lilly; Novartis; Roche |
Research Funding - Bayer (Inst); Roche (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Lilly; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
Travel, Accommodations, Expenses - Bayer; Roche |